Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3475070 with or without Pembrolizumab in Advanced Solid Malignancies
NCT04148937Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of LY3475070 in breast cancer, pancreatic cancer (PC), lung cancer and 4 more (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With Dose Limiting Toxicities at 28 days. Started Jan 2020; status: completed.
02
Drugs
LY3475070
03
Conditions
breast cancerpancreatic cancer (PC)lung cancerkidney cancermelanoma
Beyond the preview
Go deeper on NCT04148937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04148937.